News & Analysis on Clinical Trial Services & Contract Research And Development
By Melissa Fassbender
- Last updated on
To strengthen its centers of development in oncology and rare/orphan diseases, the CRO has hired two new experienced leaders
A certified hematologist, Hassan Aly, MD, PhD, joins Synteract as senior medical director supporting the company's Oncology Center of Development. Prior to Synteract, he held roles at other CROs as well as AstraZeneca and Boehringer-Ingelheim.
Said Aly, “I look forward to leveraging my experience in hematology, oncology, medical research, and patient treatment across our teams to help advance treatments for hematologic diseases and hematology-based rare cancers.”